Growth Hormone Deficiency Clinical Trials 2023

Growth Hormone Deficiency Clinical Trials 2023

Growth Hormone Deficiency research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in growth hormone deficiency clinical trials today.

Houston, Texas

Hormone Therapy

Nutropin for Human Growth Hormone Deficiency

Recruiting2 awards2 criteria
Houston, Texas

The purpose of the proposed study is to investigate the effects of rhGH treatment on glucose, protein and fat metabolism in GHD children. Specifically, the investigators will measure the rates of glucose production, gluconeogenesis, glycogenolysis, insulin sensitivity and glucagon response before and after treatment with rhGH. In addition, the investigators will study changes in protein and fat metabolism pre and post rhGH therapy in children with GHD. The findings in the GHD children will be compared to those of a control group of age and sex matched healthy children. Hypotheses: H1- The fraction of glucose derived from gluconeogenesis is decreased and that from glycogenolysis is increased in the post-absorptive state in untreated GHD children when compared to healthy children. H2- Treatment with rhGH will not change the overall glucose turnover but will normalize the abnormal partitioning of gluconeogenesis and glycogenolysis in GHD children. H3- GH replacement will reduce urea production and increase estimates of protein synthesis, thus optimizing the availability of amino acids for growth. H4- Untreated children with GHD after an overnight fast will have an increased glucagon challenge response that will decrease after 8 weeks of treatment with rhGH. Specific Aims: In healthy and newly diagnosed GHD children the investigators will: 1. Measure the Glucose Production Rate (GPR) 2. Determine the fraction of glucose derived from gluconeogenesis and glycogenolysis 3. Estimate insulin sensitivity 4. Measure proteolysis and protein oxidation 5. Determine glucagon challenge response after an overnight fast. The above-mentioned parameters will be re-evaluated in the children with GHD after 8 weeks of rhGH therapy.

Trials for GHD Patients

Trials for Pituitary Tumors Patients

Toronto, Ontario


Electrocautery versus scalpel for Pituitary Tumors

Recruiting1 award2 criteria
Toronto, Ontario

Pituitary tumours have an estimated prevalence of 20% in the general population and the number of clinically relevant pituitary adenomas is increasing with time. When symptomatic, the standard of care required for pituitary adenomas is resection through an endoscopic transsphenoidal approach. There is however significant olfactory dysfunction following endoscopic transsphenoidal pituitary surgery with approximately 23% of patients reporting some degree of worsening in their sense of smell in the postoperative period. Pedicled nasoseptal flaps are used to repair skull base defects following resection of skull base tumours. The superior incision is placed in close proximity to olfactory mucosa. Currently, these flaps are raised either with the use of electrocautery or scalpel. The use of electrocautery in surgery has provided surgeons with greater hemostasis when compared to a scalpel. This is of utmost importance in many regions of the head & neck where highly vascularized tissue results in difficulties achieving adequate hemostasis and therefore limiting view of the surgical field. However, the use of electrocautery increases thermal damage to surrounding tissue and impairs wound healing when compared to a scalpel. Although the transmission of thermal energy via electrocautery to adjacent mucosa containing olfactory epithelium may theoretically contribute to olfactory disturbances, no prospective randomized controlled trials have yet examined the impact of these two different techniques on postoperative olfactory function. The purpose of this research study is to determine the effects, if any, of electrocautery versus scalpel on olfaction in raising the nasoseptal flap for repairing skull base defects following transphenoidal surgery.

Phase 3 Trials

Trials With No Placebo

Portland, Oregon

Growth Hormone Receptor Antagonist

Pegvisomant for Adult Growth Hormone Deficiency

Recruiting2 awards4 criteria
Portland, Oregon

Hypothesis: Pegvisomant combined with the glucagon stimulation test (GST) can improve the accuracy of this test when used to diagnose adult GH and cortisol (steroid hormone)insufficiency. Study aims: Diagnosing GH and cortisol deficiency in adults requires a special test. At present, the insulin tolerance test (ITT) is considered the test of choice. However, this test is difficult to perform as it involves giving insulin through the veins to decrease blood sugars to very low levels, and this can be unpleasant, and cannot be performed in elderly adults and in those with a history of heart disease, seizure disorders or stroke. For this reason there is an urgent need for an alternative reliable test. At present, the GST is considered the alternative test to the ITT but its accuracy in obese patients and in those with diabetes remains unclear. Pegvisomant is a medication that can increase GH production in the body. The purpose of this study is to find out if combining pegvisomant with the GST can help improve the accuracy of this test so that it is comparable with the ITT in diagnosing adult GH and cortisol insufficiency. Study design: Subjects will be recruited from the Oregon Health & Science University Dynamic Endocrine Testing Unit. A written informed consent will be obtained and a screening interview will be carried out. During the screening interview, the study will be explained to the subject in detail. For women of child-bearing age, a pregnancy test will be performed. The subjects will then take part in three studies on separate days: (1) GST; (2) pegvisomant (1 mg/kg) injection into the abdomen 3 days before the glucagon stimulation test (ii) insulin tolerance test. For the GST, glucagon will be injected into the muscle and blood draws will be performed every 30 mins for 240 mins. For the insulin tolerance test, a blood draw will be performed and insulin will be given into the vein followed by blood draws every 15 mins for 120 mins. The data from all three studies will be analyzed in the study where the peak growth hormone and cortisol levels for all three tests will be compared. A questionnaire will be used at the end of the study for the subjects to rank the level of preference of the three tests. The data of the study will be analyzed using a computer statistical program where the identity of the subjects will be coded to maintain confidentiality.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to growth hormone deficiency

What are the top hospitals conducting growth hormone deficiency research?

When it comes to advancements in the field of growth hormone deficiency, several top hospitals are leading the way with their clinical trials. In Nashville, Vanderbilt University Medical Center is currently conducting two active trials focused on this condition. Although they do not have any all-time trials recorded yet, their dedication to research and innovation shows great promise for future breakthroughs. Meanwhile, at Children's National Hospital in Washington, researchers have also embarked on two active growth hormone deficiency trials. With a total of two all-time trials under their belt since starting their first investigation in 2020, they are making significant strides in understanding this complex condition.

The University of Iowa in Iowa City has joined the ranks with its own ongoing studies on growth hormone deficiency. They currently have two active clinical trials and have conducted three all-time trials thus far since launching their initial study back in 2017. Similarly situated at UMass Memorial Medical Center in Worcester where there are also engaged towards carrying out investigations for an equal number of current growth hormone deficiencies cases plus already adding up couple more experiments which makes them pioneers from initiating trial records until recent years near2009

Last but not least is Seattle Children's Hospital located right by the scenic landscapes of Seattle; it has likewise been actively involved by conducting two ongoing clinical tests that tackle growth hormone deficiency head-on.Even though being relatively new like others started around same period as wellin 2009 that hospital stands tall showcasing commitment via participating similar count-all time examination endeavors related to such conditions.

These dedicated hospitals across different locations demonstrate a shared goal of improving outcomes for individuals affected by growth hormone deficiency through cutting-edge research and compassionate care. With each trial conducted and every discovery made, these institutions bring us closer to a better understanding of this condition and potential treatments that can transform lives.

Which are the best cities for growth hormone deficiency clinical trials?

Seattle, Washington; New york, New York; Cincinnati, Ohio; Phoenix, Arizona; and Fort Worth, Texas emerge as key cities for growth hormone deficiency clinical trials. Seattle and New York share the highest number of active trials with 6 each. These studies investigate treatments like Lonapegsomatropin, Somatropin, LUM-201, Nivolumab, somapacitan, Infigratinib 0.128 mg/kg, Nasal saline irrigation plus Standard Nasal Care + Oral Antibiotics respectively. Meanwhile Cincinnati has 4 active trials studying somapacitan and others while Phoenix also has 4 active trials examining Lonapegsomatropin alongside other interventions. Lastly Fort Worth offers 3 active trials exploring GenSci004 in addition to LUM-201 and somapacitan among others. These cities provide opportunities for individuals with growth hormone deficiency to participate in cutting-edge clinical research aimed at improving treatment options and enhancing quality of life.

Which are the top treatments for growth hormone deficiency being explored in clinical trials?

Clinical trials are paving the way for breakthroughs in treating growth hormone deficiency. Among the top contenders is somapacitan, currently undergoing two active trials dedicated to this condition. Since its introduction in 2012, it has been enlisted in a total of eight growth hormone deficiency trials. Another frontrunner is lonapegsomatropin, which made its debut just last year but is already making waves with two ongoing clinical trials focused on addressing growth hormone deficiency. These innovative treatments demonstrate great promise and may offer new hope for individuals affected by this hormonal disorder.

What are the most recent clinical trials for growth hormone deficiency?

Groundbreaking clinical trials are shedding new light on the treatment of growth hormone deficiency. One recent study focused on LUM-201, administering a dosage of 1.6 mg/kg/day to individuals with this condition during its Phase 2 trial. Similarly, lonapegsomatropin underwent Phase 3 testing and displayed promising results for growth hormone deficiency patients. Another noteworthy trial involved rollover subjects in Arm 1, further contributing to our understanding of potential treatments for this condition during its Phase 2 stage. With these advancements in medical research, we move closer to developing innovative therapies that can improve the lives of those affected by growth hormone deficiency.

What growth hormone deficiency clinical trials were recently completed?

Recently completed clinical trials have made significant strides in addressing growth hormone deficiency. In December 2017, Ascendis Pharma A/S concluded a trial that focused on TransCon hGH therapy. This breakthrough treatment offers hope for individuals with growth hormone deficiencies and showcases the dedication of researchers in advancing medical interventions for this condition.